explore -WSS

explore

author：comprehensive 2025-09-27 12:35:14 - browse：55441

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation.

Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

For more on what we cover, here’s STAT’s investigation into the Mount Sinai brain-tissue research project; here’s exclusive reporting on the MorphoSys drug at the center of the Novartis acquisition, and Adam Feuerstein’s take on where it might run off the rails; and here’s STAT’s reporting on Novo Nordisk and its weight loss drug Wegovy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Covid vaccine financial winners and losers, from Pfizer to Novavax

hotspot

WSS

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Drug companies' payments and gifts affect physicians' prescribing

The Readout: Lenmeldy, GLP

There's no autism epidemic. It's an autism diagnosis epidemic

Readout LOUD podcast: mifepristone case, GLP

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Medicare proposal to cover medical devices draws a mixed reaction

Researchers test human milk's ability to repair gut microbiome

Anesthesiologist group: stop taking Ozempic before surgery

Trial using CRISPR to edit HIV out of cells disappoints

ChatGPT in medicine: STAT answers readers' burning questions

Readout Newsletter: Merck, Vertex, and Viking updates

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

U.K. decision on ALS drug has neurologists, advocates up in arms

Walensky prepares to leave CDC — and Congress — behind

Trial using CRISPR to edit HIV out of cells disappoints

focus

Bird flu in dairy cattle: New measures to control spread to humans

Trial using CRISPR to edit HIV out of cells disappoints

Harvard scientists, with Google, unveil the most detailed brain map ever

Decaf coffee targeted by food safety group under obscure FDA rule

Gut bacteria may contribute to kidney autoimmunity, study finds

Drug companies' payments and gifts affect physicians' prescribing

focus

hotspot

focus

hotspot